NPM1 and acute myeloid leukemia: recently summarized how he diagnose and treat NPM1-mutated AML and he constructively proposed that NPM1 mutational status, the timing of HSCT, MRD monitoring and ELN genetic-based risk stratification should be considered during the therapy (99).